FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224252110> ?p ?o ?g. }

• W4224252110 endingPage "E49" @default.
• W4224252110 startingPage "E48" @default.
• W4224252110 abstract "To the editor, We have recently studied the article “Effect of Diabetes Medications and Glycemic Control on Risk of Hepatocellular Cancer in Patients with Nonalcoholic Fatty Liver Disease” published in hepatology by Kramer et al.[1] This article is a large retrospective cohort study of more than 85,000 patients with both Type 2 diabetes and NAFLD, which describes the effect of diabetes medication use and glycemic control on the development of HCC and finds that metformin alone reduces the incidence of HCC by 50%, while the combination increases it, providing strong data to support a reduction in HCC incidence. However, there are several issues to be aware of in this study. First, there were some issues with the selection of the study population. Patients with NAFLD were selected to exclude HBV simply because of the absence of HBsAg positivity. The persistence and detection of serum or liver HBV DNA in the absence of serum HBsAg are defined as occult HBV infection (OBI).[2] The status of occult infection is mainly associated with suppression of viral replication and gene expression; however, it is also seen in patients with mutant HBV whose HBsAg is undetectable. In one prospective study, multifactorial analysis confirmed that OBI is an independent risk factor for hepatocarcinogenesis in patients with cryptogenic cirrhosis.[3] This suggests the possible presence of patients with HBV among the patients with NAFLD selected for this study, which has an impact on the accuracy of the final conclusions drawn. In addition, patients with NAFLD and diabetes were selected for the study with varying degrees of severity of disease. They should be further grouped for different degrees of metabolic syndrome, using propensity score matching. If a patient has a more severe metabolic syndrome, their metabolic indications are difficult to control, and they develop HCC after the combination of drugs, it is not certain whether it is due to drug factors or their own disease. Or if the patients treated with metformin have mild disease, whether it is the anticancer properties of metformin or the mild metabolic syndrome that does not lead to HCC, we can use metformin alone and in combination for the same group of patients after group scoring and then analyze their effect on the incidence of HCC. Finally, the results of the current study are more applicable to Europeans, with study data from the US Department of Veterans Affairs (VA) Corporate Data Warehouse and the VA Central Cancer Registry.[1] In contrast, Asian or other populations from different continents may show different results depending on factors such as geography, dietary structure, and religious beliefs.[4] Therefore, we propose that multicenter studies should be conducted to refine the effect of diabetes medications and glycemic control as well as other metabolically related factors on the development of HCC in patients with NAFLD and diabetes in cohorts of different ethnic groups. Thus, the conclusion that metformin use is associated with a reduced risk of HCC while combination therapy use is associated with an increased risk needs further validation. FUNDING INFORMATION Supported by the Wang Bao 'en Liver Fibrosis Research Fund of the China Hepatitis Prevention and Control Foundation (WEB2021038) CONFLICT OF INTEREST Nothing to report. AUTHOR CONTRIBUTIONS Writing: Yibing Zhou. Writing and critical revision: Weike Chu, Xue Wu, Hui Zhou, Bin Niu, Ze Chen. Critical revision: Yuqiang Mi and Ping Li." @default.
• W4224252110 created "2022-04-26" @default.
• W4224252110 creator A5003508637 @default.
• W4224252110 creator A5004128889 @default.
• W4224252110 creator A5009834783 @default.
• W4224252110 creator A5031875473 @default.
• W4224252110 creator A5049247166 @default.
• W4224252110 creator A5065747688 @default.
• W4224252110 creator A5081126717 @default.
• W4224252110 creator A5082415103 @default.
• W4224252110 date "2022-04-20" @default.
• W4224252110 modified "2023-10-11" @default.
• W4224252110 title "Letter to the editor: Effect of diabetes medications and glycemic control on risk of HCC in patients with NAFLD" @default.
• W4224252110 cites W2765567315 @default.
• W4224252110 cites W3033451374 @default.
• W4224252110 doi "https://doi.org/10.1002/hep.32504" @default.
• W4224252110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35366349" @default.
• W4224252110 hasPublicationYear "2022" @default.
• W4224252110 type Work @default.
• W4224252110 citedByCount "0" @default.
• W4224252110 crossrefType "journal-article" @default.
• W4224252110 hasAuthorship W4224252110A5003508637 @default.
• W4224252110 hasAuthorship W4224252110A5004128889 @default.
• W4224252110 hasAuthorship W4224252110A5009834783 @default.
• W4224252110 hasAuthorship W4224252110A5031875473 @default.
• W4224252110 hasAuthorship W4224252110A5049247166 @default.
• W4224252110 hasAuthorship W4224252110A5065747688 @default.
• W4224252110 hasAuthorship W4224252110A5081126717 @default.
• W4224252110 hasAuthorship W4224252110A5082415103 @default.
• W4224252110 hasBestOaLocation W42242521101 @default.
• W4224252110 hasConcept C120665830 @default.
• W4224252110 hasConcept C121332964 @default.
• W4224252110 hasConcept C126322002 @default.
• W4224252110 hasConcept C134018914 @default.
• W4224252110 hasConcept C203014093 @default.
• W4224252110 hasConcept C2522874641 @default.
• W4224252110 hasConcept C2776954865 @default.
• W4224252110 hasConcept C2777180221 @default.
• W4224252110 hasConcept C2777214474 @default.
• W4224252110 hasConcept C2777410769 @default.
• W4224252110 hasConcept C2778772119 @default.
• W4224252110 hasConcept C2779134260 @default.
• W4224252110 hasConcept C2779306644 @default.
• W4224252110 hasConcept C2780323712 @default.
• W4224252110 hasConcept C2780473172 @default.
• W4224252110 hasConcept C2780593183 @default.
• W4224252110 hasConcept C2908647359 @default.
• W4224252110 hasConcept C41260117 @default.
• W4224252110 hasConcept C555293320 @default.
• W4224252110 hasConcept C61511704 @default.
• W4224252110 hasConcept C71924100 @default.
• W4224252110 hasConcept C90924648 @default.
• W4224252110 hasConcept C99454951 @default.
• W4224252110 hasConceptScore W4224252110C120665830 @default.
• W4224252110 hasConceptScore W4224252110C121332964 @default.
• W4224252110 hasConceptScore W4224252110C126322002 @default.
• W4224252110 hasConceptScore W4224252110C134018914 @default.
• W4224252110 hasConceptScore W4224252110C203014093 @default.
• W4224252110 hasConceptScore W4224252110C2522874641 @default.
• W4224252110 hasConceptScore W4224252110C2776954865 @default.
• W4224252110 hasConceptScore W4224252110C2777180221 @default.
• W4224252110 hasConceptScore W4224252110C2777214474 @default.
• W4224252110 hasConceptScore W4224252110C2777410769 @default.
• W4224252110 hasConceptScore W4224252110C2778772119 @default.
• W4224252110 hasConceptScore W4224252110C2779134260 @default.
• W4224252110 hasConceptScore W4224252110C2779306644 @default.
• W4224252110 hasConceptScore W4224252110C2780323712 @default.
• W4224252110 hasConceptScore W4224252110C2780473172 @default.
• W4224252110 hasConceptScore W4224252110C2780593183 @default.
• W4224252110 hasConceptScore W4224252110C2908647359 @default.
• W4224252110 hasConceptScore W4224252110C41260117 @default.
• W4224252110 hasConceptScore W4224252110C555293320 @default.
• W4224252110 hasConceptScore W4224252110C61511704 @default.
• W4224252110 hasConceptScore W4224252110C71924100 @default.
• W4224252110 hasConceptScore W4224252110C90924648 @default.
• W4224252110 hasConceptScore W4224252110C99454951 @default.
• W4224252110 hasIssue "2" @default.
• W4224252110 hasLocation W42242521101 @default.
• W4224252110 hasLocation W42242521102 @default.
• W4224252110 hasOpenAccess W4224252110 @default.
• W4224252110 hasPrimaryLocation W42242521101 @default.
• W4224252110 hasRelatedWork W2033851814 @default.
• W4224252110 hasRelatedWork W2035964160 @default.
• W4224252110 hasRelatedWork W2043316108 @default.
• W4224252110 hasRelatedWork W2063868487 @default.
• W4224252110 hasRelatedWork W2072873519 @default.
• W4224252110 hasRelatedWork W2317406634 @default.
• W4224252110 hasRelatedWork W2795193998 @default.
• W4224252110 hasRelatedWork W2910810269 @default.
• W4224252110 hasRelatedWork W3034993656 @default.
• W4224252110 hasRelatedWork W4239699423 @default.
• W4224252110 hasVolume "76" @default.
• W4224252110 isParatext "false" @default.
• W4224252110 isRetracted "false" @default.
• W4224252110 workType "letter" @default.